Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493769 | 0.89 | CA1 (0.41) | CA1CA2TDP1ABL1PDGFRB | |
| SCHEMBL5492776 | 0.89 | ITGA4 (0.36) | TDP1KDM4ETLR7WDR5ITGA4 | |
| SCHEMBL6066213 | 0.83 | TDP1 (0.36) | CA1CA2TDP1KDM4EITGA4 | |
| SCHEMBL5493766 | 0.77 | TLR7 (0.37) | CA1CA2KDM4ETLR7WDR5 | |
| SCHEMBL28755118 | 0.77 | KMT2A (0.32) | SRCMAPK14ITGA4ITGB7 | |
| SCHEMBL5148644 | 0.77 | KDM4E (0.41) | CA1CA2TDP1KDM4EPOLB | |
| SCHEMBL5494797 | 0.77 | ITGA4 (0.36) | ITGA4ITGB7 | |
| SCHEMBL5494802 | 0.77 | ITGA4 (0.36) | ITGA4ITGB7 | |
| SCHEMBL5493771 | 0.76 | CCNC (0.41) | CA1CA2TDP1POLBALDH1A1 | |
| SCHEMBL5500017 | 0.75 | TLR7 (0.36) | CA1CA2KDM4ETLR7WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| CN-1708502-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | CA1 3697/4885CA2 997/4885TDP1 3818/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | CA1 3104/4885CA2 691/4885TDP1 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.